Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Spectrum Pharmaceuticals, Inc
Study ID
NCT00055887
Phase
PHASE3
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • carboplatin — DRUG
  • cisplatin — DRUG
  • efaproxiral — DRUG
  • gemcitabine hydrochloride — DRUG
  • paclitaxel — DRUG
  • vinorelbine ditartrate — DRUG
  • radiation therapy — PROCEDURE

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as efaproxiral may make the tumor cells more sensitive to radiation therapy. It is not yet known if chemotherapy combined with radiation therapy is more effective with or without efaproxiral in treating non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy combined with radiation therapy with or without efaproxiral in treating patients who have stage III non-small cell lung cancer.

Key Dates

Start date
Nov 30, 2002
Status verified
May 2013

Study Design

Enrollment
0 participants (actual)
Allocation
RANDOMIZED
Primary purpose
TREATMENT

Locations (8)

FacilityCityStateZIPSite coordinators
St. Joseph's Hospital and Medical CenterPhoenixArizona85013-
North Idaho Cancer CenterCoeur d'AleneIdaho83814-
Cancer Center at Lexington ClinicLexingtonKentucky40504-
Willis - Knighton Cancer CenterShreveportLouisiana71103-3951-
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimoreMaryland21231-2410-
St. Agnes Cancer CenterBaltimoreMaryland21229-
Providence Everett Medical Center - Pacific CampusEverettWashington98206-
Schiffler Cancer CenterWheelingWest Virginia26003-

Find similar trials in Phoenix, AZ

By condition

Related Studies